+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multiple Sclerosis Therapeutic Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressants, Immunostimulants), By Route Of Administration (Oral, Injectable), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030- Product Image
Multiple Sclerosis Therapeutic Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressants, Immunostimulants), By Route Of Administration (Oral, Injectable), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030- Product Image
New

Multiple Sclerosis Therapeutic Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressants, Immunostimulants), By Route Of Administration (Oral, Injectable), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 150 Pages
  • June 2025
  • Region: Global
  • Grand View Research
  • ID: 5999056
Description Jump to:

Multiple Sclerosis Therapeutic Market Growth & Trends

The global multiple sclerosis therapeutic market size is estimated to reach USD 38.62 billion by 2030, registering a CAGR of 5.93% from 2025 to 2030. The presence of high unmet clinical needs in developing regions is one of the highest impact rendering drivers of the multiple sclerosis therapeutics market. Many organizations over the globe are actively involved in spreading awareness among people regarding progressive multiple sclerosis and the symptoms associated with it. Some notable examples include the National Multiple Sclerosis Society (NMSS) in the U.S., Multiple Sclerosis International Federation in Canada, European Multiple Sclerosis Platform (EMSP), and the Multiple Sclerosis Society (MSC).

Reimbursement programs are also anticipated to enhance the penetration of multiple sclerosis drugs. For instance, In June 2014, Biogen Idec Canada, announced that its TECFIDERA drug for the treatment of MS is available for reimbursement in British Colombia through B.C PharmaCare.

The introduction of novel therapeutics with minimal dosage requirement and cost-effectiveness is further expected to favor market growth. For, instance Lemtrada by Sanofi needs to be administered 3-5 times per year as compared to Copaxone, which requires daily administration.

Multiple Sclerosis Therapeutic Market Report Highlights

  • Based on drug class, the immunosuppressant segment dominated the market with the largest revenue share of 60.50% in 2024. The presence of a strong drug pipeline and its expected commercialization in the coming six years are some factors expected to drive market growth.
  • Based on route of administration, the oral segment is expected to grow at the fastest CAGR rate over the forecast period, propelled by increasing patient preference for convenient, home-based treatment options.
  • In 2024, the injectable market held the largest share of 52.50% in 2024, owing to high prescription rates & price.
  • North America dominated the global market with a share of 38.28% in 2024. The increasing prevalence of multiple sclerosis, the introduction of new drugs, and high prices of drugs, such as Tysabri and Aubagio in the U.S., are some factors responsible for its dominance.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Multiple Sclerosis Therapeutics Market Variables, Trends & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Multiple Sclerosis Therapeutic Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
3.4.3. Pipeline Analysis, By Phase
Chapter 4. Multiple Sclerosis Therapeutics Market: Drug Class Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Multiple Sclerosis Therapeutic Market: Drug Class Movement Analysis, 2024 & 2030 (USD Million)
4.3. Immunosuppressants
4.3.1. Immunosuppressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Immunostimulants
4.4.1. Immunostimulants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Multiple Sclerosis Therapeutics Market: Route of Administration Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Multiple Sclerosis Therapeutic Market: Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
5.3. Oral
5.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Injectable
5.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Multiple Sclerosis Therapeutics Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Multiple Sclerosis Therapeutic Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
6.3. Hospital Pharmacies
6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacies
6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. E-Commerce
6.5.1. E-Commerce Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Multiple Sclerosis Therapeutic Market: Regional Estimates & Trend Analysis
7.1. Multiple Sclerosis Therapeutic Market Share, By Region, 2024 & 2030 (USD Million)
7.2. North America
7.2.1. North America Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Australia Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Teva Pharmaceutical Industries Ltd.
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Pfizer Inc.
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Biogen
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Bayer AG
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Sanofi
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. F. Hoffman-La Roche Ltd
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Johnson & Johnson Services, Inc.
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Merck & Co., Inc.
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Takeda Pharmaceuticals Company Limited.
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Horizon Therapeutics plc
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 4 Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 5 Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 6 North America Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 7 North America Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 8 North America Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 9 North America Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 10 U.S Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 11 U.S Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 12 U.S Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 13 Canada Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 14 Canada Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 15 Canada Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 16 Mexico Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 17 Mexico Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 18 Mexico Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 19 Europe Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 20 Europe Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 21 Europe Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 22 Europe Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 23 UK Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 24 UK Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 25 UK Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 26 Germany Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 27 Germany Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million))
Table 28 Germany Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 29 France Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 30 France Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 31 France Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 32 Italy Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 33 Italy Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 34 Italy Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 35 Spain Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 36 Spain Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 37 Spain Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 38 Denmark Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 39 Denmark Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 40 Denmark Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 41 Sweden Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 42 Sweden Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 43 Sweden Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 44 Norway Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 45 Norway Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 46 Norway Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 47 Asia Pacific Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 48 Asia Pacific Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 49 Asia Pacific Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 50 Asia Pacific Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 51 Japan Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 52 Japan Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 53 Japan Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 54 China Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 55 China Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 56 China Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 57 India Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 58 India Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 59 India Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 60 South Korea Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 61 South Korea Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 62 South Korea Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 63 Australia Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 64 Australia Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 65 Australia Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 66 Thailand Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 67 Thailand Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 68 Thailand Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 69 Latin America Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 70 Latin America Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 71 Latin America Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 72 Latin America Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 73 Brazil Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 74 Brazil Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 75 Brazil Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 76 Argentina Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 77 Argentina Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 78 Argentina Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 79 Middle East & Africa Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 80 Middle East & Africa Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 81 Middle East & Africa Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 82 Middle East & Africa Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 83 South Africa Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 84 South Africa Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 85 South Africa Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 86 UAE Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 87 UAE Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 88 UAE Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 89 Kuwait Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 90 Kuwait Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 91 Kuwait Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Multiple Sclerosis Therapeutics Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 Multiple Sclerosis Therapeutics market: Drug Class outlook and key takeaways
Fig. 15 Multiple Sclerosis Therapeutics market: Drug Class movement analysis & market share 2024 & 2030
Fig. 16 Immunosuppressants market, 2018 - 2030 (USD Million)
Fig. 17 Immunostimulants market, 2018 - 2030 (USD Million)
Fig. 18 Multiple Sclerosis Therapeutics market: Route of Administration outlook and key takeaways
Fig. 19 Multiple Sclerosis Therapeutics market: Route of Administration movement analysis & market share 2024 & 2030
Fig. 20 Oral Multiple Sclerosis Therapeutics market, 2018 - 2030 (USD Million)
Fig. 21 Injectable Multiple Sclerosis Therapeutics market, 2018 - 2030 (USD Million)
Fig. 22 Others Multiple Sclerosis Therapeutics market, 2018 - 2030 (USD Million)
Fig. 23 Multiple Sclerosis Therapeutics market: Distribution Channel outlook and key takeaways
Fig. 24 Multiple Sclerosis Therapeutics market: Distribution Channel movement analysis & market share 2024 & 2030
Fig. 25 Hospital Pharmacies, 2018 - 2030 (USD Million)
Fig. 26 Retail Pharmacies, 2018 - 2030 (USD Million)
Fig. 27 E-Commerce, 2018 - 2030 (USD Million)
Fig. 28 Regional Marketplace: Key Takeaways
Fig. 29 Regional Outlook, 2024 & 2030
Fig. 30 Regional Market Dashboard
Fig. 31 Regional Market Place: Key Takeaways
Fig. 32 North America
Fig. 33 North America Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 34 U.S. Key Country Dynamics
Fig. 35 U.S. Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 36 Canada Key Country Dynamics
Fig. 37 Canada Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 38 Mexico Key Country Dynamics
Fig. 39 Mexico Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 40 Europe
Fig. 41 Europe Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 42 UK Key Country Dynamics
Fig. 43 UK Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 44 Germany Key Country Dynamics
Fig. 45 Germany Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 46 France Key Country Dynamics
Fig. 47 France Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 48 Italy Key Country Dynamics
Fig. 49 Italy Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 50 Spain Key Country Dynamics
Fig. 51 Spain Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 52 Denmark Key Country Dynamics
Fig. 53 Denmark Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 54 Sweden Key Country Dynamics
Fig. 55 Sweden Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 56 Norway Key Country Dynamics
Fig. 57 Norway Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 58 Asia Pacific
Fig. 59 Asia-Pacific Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 60 Japan Key Country Dynamics
Fig. 61 Japan Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 62 China Key Country Dynamics
Fig. 63 China Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 64 India Key Country Dynamics
Fig. 65 India Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 66 Australia Key Country Dynamics
Fig. 67 Australia Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 68 Thailand Key Country Dynamics
Fig. 69 Thailand Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 70 South Korea Key Country Dynamics
Fig. 71 South Korea Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 72 Latin America
Fig. 73 Latin America Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 74 Brazil Key Country Dynamics
Fig. 75 Brazil Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 76 Argentina Key Country Dynamics
Fig. 77 Argentina Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 78 MEA
Fig. 79 MEA Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 80 South Africa Key Country Dynamics
Fig. 81 South Africa Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 82 Saudi Arabia Key Country Dynamics
Fig. 83 Saudi Arabia Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 84 UAE Key Country Dynamics
Fig. 85 UAE Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 86 Kuwait Key Country Dynamics
Fig. 87 Kuwait Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 88 Strategy Mapping

Companies Mentioned

  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Biogen
  • Bayer AG
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company Limited.
  • Horizon Therapeutics plc

Table Information

Report AttributeDetails
No. of Pages150
PublishedJune 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 27.39 Billion
Forecasted Market Value ( USD ) by 2030 $ 38.62 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Multiple Sclerosis Therapeutics - Global Strategic Business Report - Product Image

Multiple Sclerosis Therapeutics - Global Strategic Business Report

  • Report
  • 268 Pages
  • Global
From
Multiple Sclerosis Market by Multiple Sclerosis Type, Mechanism of Action, Route of Administration, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Multiple Sclerosis Market by Multiple Sclerosis Type, Mechanism of Action, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report by Disease, Drug Class (Anticonvulsants, CNS Stimulants), Distribution Channel, Region, and Segment Forecasts, 2025-2030 - Product Image

Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report by Disease, Drug Class (Anticonvulsants, CNS Stimulants), Distribution Channel, Region, and Segment Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Neurodegenerative Drugs Market by Type, Drug Class, Mode Of Administration, Mechanism Of Action, Therapeutic Approach, Indication, Patient Demographics, Sales Channel, End User - Global Forecast to 2030 - Product Image

Neurodegenerative Drugs Market by Type, Drug Class, Mode Of Administration, Mechanism Of Action, Therapeutic Approach, Indication, Patient Demographics, Sales Channel, End User - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Relapsing Remitting Multiple Sclerosis Market - Product Image

Relapsing Remitting Multiple Sclerosis Market

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.